Home Healthcare Biotechnology Immune Checkpoint Inhibitors Market

Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report By Type (PD-1 Inhibitor, PD-L1 Inhibitor, CTLA-4 Inhibitor, Others), By Applications (Lung Cancer, Breast Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin Lymphoma, Cervical Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Immune Checkpoint Inhibitors Market, By Type 2022-2034 (USD MILLION/ Units)
    1. PD-1 Inhibitor
    2. PD-L1 Inhibitor
    3. CTLA-4 Inhibitor
    4. Others
  2. Immune Checkpoint Inhibitors Market, By Applications 2022-2034 (USD MILLION/ Units)
    1. Lung Cancer
    2. Breast Cancer
    3. Bladder Cancer
    4. Melanoma
    5. Colorectal Cancer
    6. Hodgkin Lymphoma
    7. Cervical Cancer
    8. Others
  3. Immune Checkpoint Inhibitors Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  4. Regional Immune Checkpoint Inhibitors Market
    1. North America
      1. North America Immune Checkpoint Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
      2. North America Immune Checkpoint Inhibitors Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Bladder Cancer
        4. Melanoma
        5. Colorectal Cancer
        6. Hodgkin Lymphoma
        7. Cervical Cancer
        8. Others
      3. North America Immune Checkpoint Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. U.S.
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      5. Canada
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
    2. Europe
      1. Europe Immune Checkpoint Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
      2. Europe Immune Checkpoint Inhibitors Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Bladder Cancer
        4. Melanoma
        5. Colorectal Cancer
        6. Hodgkin Lymphoma
        7. Cervical Cancer
        8. Others
      3. Europe Immune Checkpoint Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. U.K.
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      5. Germany
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      6. France
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      7. Spain
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      8. Italy
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      9. Russia
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      10. Nordic
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      11. Benelux
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      12. Rest of Europe
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
    3. APAC
      1. APAC Immune Checkpoint Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
      2. APAC Immune Checkpoint Inhibitors Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Bladder Cancer
        4. Melanoma
        5. Colorectal Cancer
        6. Hodgkin Lymphoma
        7. Cervical Cancer
        8. Others
      3. APAC Immune Checkpoint Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. China
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      5. Korea
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      6. Japan
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      7. India
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      8. Australia
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      9. Taiwan
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      10. South East Asia
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      11. Rest of Asia-Pacific
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Immune Checkpoint Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
      2. Middle East and Africa Immune Checkpoint Inhibitors Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Bladder Cancer
        4. Melanoma
        5. Colorectal Cancer
        6. Hodgkin Lymphoma
        7. Cervical Cancer
        8. Others
      3. Middle East and Africa Immune Checkpoint Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. UAE
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      5. Turkey
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      6. Saudi Arabia
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      7. South Africa
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      8. Egypt
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      9. Nigeria
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      10. Rest of MEA
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
    5. LATAM
      1. LATAM Immune Checkpoint Inhibitors Market By Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
      2. LATAM Immune Checkpoint Inhibitors Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Lung Cancer
        2. Breast Cancer
        3. Bladder Cancer
        4. Melanoma
        5. Colorectal Cancer
        6. Hodgkin Lymphoma
        7. Cervical Cancer
        8. Others
      3. LATAM Immune Checkpoint Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. Brazil
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      5. Mexico
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      6. Argentina
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      7. Chile
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      8. Colombia
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
      9. Rest of LATAM
        1. PD-1 Inhibitor
        2. PD-L1 Inhibitor
        3. CTLA-4 Inhibitor
        4. Others
        5. Lung Cancer
        6. Breast Cancer
        7. Bladder Cancer
        8. Melanoma
        9. Colorectal Cancer
        10. Hodgkin Lymphoma
        11. Cervical Cancer
        12. Others
        13. Hospital Pharmacies
        14. Retail Pharmacies
        15. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.